Current and emerging pharmacological treatment options for patients with dry eye disease

ABSTRACT Introduction To provide an up-to-date overview of current pharmacological treatments and promising emerging therapies for dry eye disease (DED), a multifactorial and increasingly prevalent ocular surface disorder. Areas covered A targeted literature search was conducted using PubMed, Scopus, ClinicalTrials.gov, and additional online sources to identify recent advances in the pharmacological management of DED. The review focuses on therapies approved across major regulatory bodies, as well as investigational agents in late-stage clinical development. Special attention is given to novel drug delivery platforms and innovative therapeutic mechanisms. Expert opinion Rapid innovation in both therapeutic targets and drug delivery technologies is transforming the treatment landscape for DED. Advanced formulations, such as nanomicelles, mucus-penetrating particles, and preservative-free emulsions, are improving ocular bioavailability, reducing adverse effects, and enhancing patient adherence. The future of DED pharmacotherapy lies in personalized, multimodal strategies that address the full spectrum of disease mechanisms, including inflammation, tear film instability, neurosensory dysfunction, and epithelial damage. The recent FDA approval of AR-15512, a TRPM8 agonist, exemplifies the trend toward mechanism-specific therapies designed to deliver both symptomatic relief and disease modification. As the therapeutic armamentarium expands globally, continued clinical trials and real-world studies will be essential to ensure durable efficacy and optimize patient outcomes.

• Publication year

  2025

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2025-07-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17512433.2025.2543380PMID 40751370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS

  2025cited by this paper
• Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics

  2025cited by this paper
• An update on emerging pharmacological treatments for meibomian gland dysfunction

  2025cited by this paper
• Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis

  2024cited by this paper
• Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial.

  2024cited by this paper
• Oral Azithromycin versus Oral Doxycycline in the Treatment of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis

  2024cited by this paper
• Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials

  2024cited by this paper
• Navigating dry eye relief: Meibo’s approach to controlling tear evaporation

  2024cited by this paper
• Efficacy and Safety of Perfluorohexyloctane in Evaporative Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cited by this paper
• Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies

  2024cited by this paper
• Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease

  2024cited by this paper
• The evolution of cyclosporine treatments for treatment of ocular surface diseases

  2024cited by this paper
• Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial

  2024cited by this paper
• MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease

  2024cited by this paper
• Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE

  2024cited by this paper
• Enhancing Corneal Drug Penetration Using Penetratin for Ophthalmic Suspensions.

  2024cited by this paper
• Patient-Reported Dry Eye Treatment and Burden of Care

  2024cited by this paper
• Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease

  2024cited by this paper
• Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application

  2024cited by this paper
• Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.

  2024cited by this paper
• Effect of different artificial tears on tear film parameters in dry eye disease

  2024cited by this paper
• Topical Ivermectin-metronidazole gel therapy improves Meibomian gland Function in blepharitis caused by demodex spp.

  2024cited by this paper
• Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial.

  2023cited by this paper
• The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis

  2023cited by this paper
• Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED

  2023cited by this paper
• Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study

  2023cited by this paper
• Topical ivermectin ointment treatment of Demodex blepharitis: a 6-year retrospective study

  2023cited by this paper
• Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

  2023influential reference
• Efficacy of Interleukin-1β Inhibitor on Dry Eye Disease in Patients with Degenerative Arthritis

  2023cited by this paper
• Recent advances in drug treatments for dry eye disease

  2023cited by this paper
• Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease

  2023cited by this paper
• Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial

  2023cited by this paper
• Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response

  2023cited by this paper
• Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial.

  2023cited by this paper
• Memory impairment in the D2.mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688

  2023influential reference
• Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).

  2023cited by this paper
• A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.

  2023cited by this paper
• 3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study

  2023cited by this paper
• Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease

  2023cited by this paper
• Tear biomarkers in dry eye disease: Progress in the last decade

  2023cited by this paper
• Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease

  2023cited by this paper
• Pulsed Oral Azithromycin vs 6-Week Oral Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: A Randomized Clinical Trial.

  2023cited by this paper
• A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives

  2023cited by this paper
• Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape

  2023cited by this paper
• Cenegermin for the treatment of dry eye disease.

  2023cited by this paper
• A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations

  2023cited by this paper
• Artificial Tears: A Systematic Review

  2023cited by this paper
• Pathophysiology of dry eye disease and novel therapeutic targets.

  2022cited by this paper
• NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.

  2022cited by this paper
• A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye

  2022influential reference
• Personalized Management of Dry Eye Disease: Beyond Artificial Tears

  2022cited by this paper
• Novel drug delivery systems for the management of dry eye.

  2022cited by this paper
• Varenicline Solution Nasal Spray: A Review in Dry Eye Disease

  2022cited by this paper
• Prevention of Surgery-Induced Dry Eye by Diquafosol Eyedrops after Femtosecond Laser-Assisted Cataract Surgery

  2022cited by this paper
• Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

  2022cited by this paper
• Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis

  2022cited by this paper
• New, potent, small molecule agonists of tyrosine kinase receptors attenuate dry eye disease

  2022cited by this paper
• Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)

  2022cited by this paper
• 'A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).

  2022cited by this paper
• Lacripep for the Treatment of Primary Sjögren–Associated Ocular Surface Disease: Results of the First-In-Human Study

  2022cited by this paper
• Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study

  2022cited by this paper
• Can the cGAS-STING Pathway Play a Role in the Dry Eye?

  2022cited by this paper
• Intranasal Varenicline: Review of a Novel Formulation for the Treatment of Dry Eye Disease

  2022cited by this paper
• Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial

  2022cited by this paper
• A synthetic tear protein resolves dry eye through promoting corneal nerve regeneration

  2022cited by this paper
• The Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign

  2022influential reference
• Topical corticosteroids for dry eye.

  2022influential reference
• Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease

  2022cited by this paper
• TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China

  2022cited by this paper
• Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?

  2022cited by this paper
• Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.

  2021cited by this paper
• A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease

  2021cited by this paper
• A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease

  2021influential reference
• Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

  2021cited by this paper
• Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome

  2021cited by this paper
• Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

  2021cited by this paper
• Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits

  2021cited by this paper
• Evaluation of Oral Rebamipide as a Potential Therapy for Sjögren Syndrome-Related Dry Eye and Mouth

  2021cited by this paper
• The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares

  2021cited by this paper
• Efficacy of Topical Ivermectin 1% in the Treatment of Demodex Blepharitis

  2021cited by this paper
• The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies

  2021cited by this paper
• Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation

  2021cited by this paper
• Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial.

  2021cited by this paper
• ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease

  2021cited by this paper
• A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments

  2020cited by this paper
• Treatment of Dry Eye from Laser-Assisted In Situ Keratomileusis With Recombinant Human Nerve Growth Factor (Cenegermin)

  2020cited by this paper
• A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease

  2020cited by this paper
• TRP Channel Cooperation for Nociception: Therapeutic Opportunities.

  2020cited by this paper
• Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.

  2020cited by this paper
• Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement

  2020cited by this paper
• Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies.

  2020cited by this paper
• Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions

  2020cited by this paper
• Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trial.

  2020influential reference
• Loteprednol Etabonate for the Treatment of Dry Eye Disease

  2020cited by this paper
• Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin

  2020cited by this paper
• Epithelial Plaque Formation Secondary to Recombinant Human Nerve Growth Factor.

  2020cited by this paper
• A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca

  2020cited by this paper
• Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles

  2020cited by this paper
• Real Life Data on Efficacy and Safety of Topical NGF Eye Drops (Cenegermin) Real-Life-Daten zur Wirksamkeit und Verträglichkeit von topischen NGF-Augentropfen (Cenegermin)

  2020cited by this paper
• A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

  2019influential reference

• Comment on "emerging oligonucleotide therapeutics for the treatment of dry eye diseases" Oligonucleotide therapeutics for dry eye disease: Navigating the road from precision promise to clinical reality

  2026cites this paper
• Current and emerging medical treatment options for corneal persistent epithelial defects

  2026cites this paper
• Polyphenol-Loaded Nanodevices as Innovative Therapeutic Strategies for Dry Eye Disease: Advances and Perspectives

  2025cites this paper
• Cyclosporine a in the treatment of dry eye disease: a narrative review

  2025cites this paper